Cyproheptadine displays preclinical activity in myeloma and leukemia

Blood

Volumn 112, Issue 3, 2008, Pages 760-769

  Mao, Xinliang ^a   Liang, Sheng Ben ^a   Hurren, Rose ^a   Gronda, Marcela ^a   Chow, Sue ^a   Wei Xu, G ^a   Wang, Xiaoming ^a   Zavareh, Reza Beheshti ^a   Jamal, Nazir ^a   Messner, Hans ^a   Hedley, David W ^a   Datti, Alessandro ^b   Wrana, Jeff L ^b   Zhu, Yuanxiao ^c   Shi, Chang Xin ^c   Lee, Kyle ^a   Tiedemann, Rodger ^c   Trudel, Suzanne ^a   Keith Stewart, A ^c   Schimmer, Aaron D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYPROHEPTADINE; CCND2 PROTEIN, HUMAN; CYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; CELL LINE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CYCLIN D1; CYCLINS; CYPROHEPTADINE; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MULTIPLE MYELOMA;

EID: 50949098862     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-142687     Document Type: Article

References (45)

1. Sherr CJ. Cancer cell cycles. Science. 1996;274: 1672-1677.
2. Sasaki Y, Jensen CT, Karlsson S, Jacobsen SE. Enforced expression of cyclin D2 enhances the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation. Blood. 2004;104:986-992.
3. Yata K, Sadahira Y, Otsuki T, et al. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1. Br J Haematol. 2001;114:591-599.
4. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 2005;65:11345-11353.
5. Hochhauser D, Schnieders B, Ercikan-Abali E, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst. 1996;88:1269-1275.
6. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G, cell cycle arrest. J Biol Chem 2006; 281:39480-39491.
7. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G, arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66:7661-7667.
8. 1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis. 2006; 27:2018-2027.
9. Bergsagel PL, Kuehl WM, Zhan F Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303.
10. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741.
11. Tinguely M, Jenni B, Reineke T et al. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays. Am J Surg Pathol. 2007;31: 690-696.
12. Hanamura I, Huang Y, Zhan F. Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20:1288-1290.
13. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
14. Mao X, Stewart AK, Hurren R, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through upregulation of ubiquitin. Blood. 2007;110:4047-4054.
15. Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48:223-226.
16. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65: 2657-2662.
17. Klein GL, Galant SP. A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis. Ann Allergy. 1980;44:142-145.
18. Mawji IA, Simpson CD, Hurren R, et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst. 2007;99:811-822.
19. Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005;105:4043-4050.
20. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bel inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007;109:5430-5438.
21. Hoy CA, Seamer LC, Schimke RT. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. Cytometry. 1989;10:718-725.
22. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet. 1977;1:862-863.
23. Schimmer AD, Hedley DW, Chow S, et al. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ. 2001;8:725-733.
24. Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther. 2004;3:1239-1248.
25. Ronchetti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood. 1999;93:1330-1337.
26. Hurt EM, Wiestner A; Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5:191-199.
27. Paterson JL, Li Z, Wen XY, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol. 2004;124:595-603.
28. Parada Y, Banerji L, Glassford J, et al. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 2001;276:23572-23580.
29. Huang W, Chang HY, Fei T, Wu H, Chen YG. GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene. 2007;26:2471-2482.
30. 1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21 [CIP1] induction. Oncogene. 1998;17:1159-1166.
31. 1 arrest and apoptosis. Proc Natl Acad Sci U SA. 1995;92:9019-9023.
32. Shift SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995:96:491-503.
33. Schimmer A, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondhal-mediated apoptosis in acute leukemia: a translational view. Blood. 2001;98:3541-3553.
34. Feldman JM, Roche J, Plonk JW. Therapeutic doses of cyproheptadine do not inhibit monoamine oxidase in man. J Clin Pharmacol. 1976; 16:106-109.
35. Remy DC, Raab AW, Rittle KE, Engelhardt EL, Scriabine A, Lotti VJ. A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having turan nuclei fused to the 10,11-vinylene bridge. J Med Chem. 1977;20:836-838.
36. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
37. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985;10:477-497.
38. Levine B. Green-Johnson D, Hogan S, Smialek JE. A cyproheptadine fatality. J Anal Toxicol. 1998;22:72-74.
39. Dutta AK, Dutta RN, Saha K. Cold urticaria. J Indian Med Assoc. 1976;66:234-237.
40. Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004;10:5692-5701.
41. Koziczak M, Hynes NE. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem. 2004:279:50004-50011.
42. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene. 2004;23:3501-3508.
43. Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 2004;103:3521-3528.
44. Trudel S. Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105:2941-2948.
45. Tiedemann R, Mao X, Shi C, et al. Identification of kinetin riboside as a novel repressor of CCND1 and CCND2 with antimyeloma activity. J Clin Invest. 2008;118:1750-1764.